Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Stevan Milhoan

Internal Medicine Vienna, WV Medical Doctor

NPI 1780661652 CMS profile 308262

2200 Grand Central Ave, Ste 110, Vienna, WV 26105

Open in the dashboard

General payments

$2,806

196 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Stevan Milhoan of Vienna, WV is reported in the CMS Open Payments database as having received $2,806 across 196 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $40 2
2021 General $24 2
2020 General $944 65
2019 General $1,797 127

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stevan Milhoan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Stevan Milhoan were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Stevan Milhoan Internal Medicine median Middle half National median
2019 $1,797 $159 $48–$570 $163
2020 $944 $119 $33–$402 $114
2021 $24 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $40 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $614 32 payments
  2. Novo Nordisk Inc $269 21 payments
  3. Kowa Pharmaceuticals America, Inc. $242 22 payments
  4. Amgen Inc. $234 16 payments
  5. GlaxoSmithKline, LLC. $206 21 payments
  6. Pfizer Inc. $192 15 payments
  7. Lilly USA, LLC $191 15 payments
  8. CSL Behring $130 8 payments
  9. Amarin Pharma Inc. $104 7 payments
  10. Allergan Inc. $92 6 payments
  11. Other $531 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,800 195 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2023
  1. FARXIGA $504 30 payments
  2. Livalo $242 22 payments
  3. Ozempic $232 19 payments
  4. Bystolic $217 20 payments
  5. JARDIANCE $191 15 payments
  6. TRULICITY $175 14 payments
  7. AIMOVIG $174 12 payments
  8. Repatha $161 11 payments
  9. TRELEGY ELLIPTA $154 17 payments
  10. Haegarda $130 8 payments
  11. Other $1,623 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 88 drugs

Part D claims

3,536

Median for Pediatric Medicine: 38

Drug cost

$208,819

Median for Pediatric Medicine: $2,769

Branded share of claims

13.6%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Januvia Sitagliptin Phosphate Brand 28 $33,491
Ozempic Semaglutide Brand 20 $32,950
Eliquis Apixaban Brand 37 $20,950
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 12 $20,059
Jardiance Empagliflozin Brand 19 $17,994
Trulicity Dulaglutide Brand 18 $16,816
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 11 $12,533
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 19 $11,684
Prempro Estrogen,con/M-Progest Acet Brand 13 $3,091
Atorvastatin Calcium Generic 292 $2,240

The 10 drugs with the highest cost, of 88 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$49,940

Medicare's payments for the services billed

Medicare patients

194

Average age 73

Services billed

652

89 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 41%
Ischemic heart disease 41%
COPD 38%
Depression 35%
Chronic kidney disease 32%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

196 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record